Clinical Trial Update: Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, pharmacokinetics, and efficacy of Paxalisib (GDC-0084) in newly diagnosed glioblastoma; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Paxalisib (GDC-0084)

Snippet

Sponsor: Kazia Therapeutics Limited | Conditions: Glioblastoma, Adult | Phase 2 | Status: COMPLETED | Results posted: 2025-03-24